Literature DB >> 29147620

Blinatumomab bridges the gap between leukemia and immunity.

Takahiro Yamazaki1, Lorenzo Galluzzi1,2,3.   

Abstract

Entities:  

Keywords:  CD19; CD4+CD25+FOXP3+ regulatory T cell; acute lymphoblastic leukemia; bispecific T-cell engager; chimeric antigen receptor; immune checkpoint blockers

Year:  2017        PMID： 29147620      PMCID： PMC5674944          DOI： 10.1080/2162402X.2017.1358335

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


× No keyword cloud information.
  46 in total

Review 1.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 2.  Trial Watch-Immunostimulation with cytokines in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Norma Bloy; Aitziber Buqué; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

3.  International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.

Authors:  Nicola Gökbuget; Hervè Dombret; Jose-Maria Ribera; Adele K Fielding; Anjali Advani; Renato Bassan; Victoria Chia; Michael Doubek; Sebastian Giebel; Dieter Hoelzer; Norbert Ifrah; Aaron Katz; Michael Kelsh; Giovanni Martinelli; Mireia Morgades; Susan O'Brien; Jacob M Rowe; Julia Stieglmaier; Martha Wadleigh; Hagop Kantarjian
Journal:  Haematologica       Date:  2016-09-01       Impact factor: 9.941

Review 4.  Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Authors:  Erika Vacchelli; Jonathan Pol; Norma Bloy; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jérôme Galon; Aurélien Marabelle; Holbrook Kohrt; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

5.  Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells.

Authors:  Srinivas Mamidi; Simon Höne; Claudia Teufel; Leopold Sellner; Thorsten Zenz; Michael Kirschfink
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

Review 6.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

Review 7.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

8.  Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses.

Authors:  Christian Hotz; Marina Treinies; Ines Mottas; Laurin C Rötzer; Anne Oberson; Lorenzo Spagnuolo; Maurizio Perdicchio; Thibaud Spinetti; Tina Herbst; Carole Bourquin
Journal:  Oncoimmunology       Date:  2016-09-09       Impact factor: 8.110

9.  Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.

Authors:  Giovanni Martinelli; Nicolas Boissel; Patrice Chevallier; Oliver Ottmann; Nicola Gökbuget; Max S Topp; Adele K Fielding; Alessandro Rambaldi; Ellen K Ritchie; Cristina Papayannidis; Lulu Ren Sterling; Jonathan Benjamin; Anthony Stein
Journal:  J Clin Oncol       Date:  2017-03-29       Impact factor: 44.544

Review 10.  Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.

Authors:  Yuval Shaked
Journal:  Nat Rev Clin Oncol       Date:  2016-04-26       Impact factor: 66.675
View more
  2 in total

Review 1.  Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Authors:  Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

Review 2.  Trial watch: Peptide-based vaccines in anticancer therapy.

Authors:  Lucillia Bezu; Oliver Kepp; Giulia Cerrato; Jonathan Pol; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.